Results 51 to 60 of about 482,990 (203)

Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment [PDF]

, 1996
BACKGROUND/AIMS: The role of cellular immunity in the clearance of hepatitis C virus after interferon therapy has not yet been elucidated. Here, we analyzed the T cell response to peptides from hepatitis C virus E1 protein in untreated and interferon ...
Borras-Cuesta, F. (Francisco), Civeira, M.P. (María Pilar), Garcia, N. (Nicolás), Jauregui, J.I. (Javier Ignacio), Lasarte, J.J. (Juan José), Prieto, J. (Jesús), Sarobe, P. (Pablo)   +6 more
core   +1 more source

Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. [PDF]

, 2013
Hepatitis C virus (HCV) is a leading cause of chronic liver disease, including chronic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.
Agnello, Aizaki, Amako, Amako, Anderson, Atsukawa, Bader, Bishop, Boulant, Bradley, Bradley, Brasaemle, Bulankina, Calland, Catherine Schuster, Chhatwal, Chojkier, Ciesek, Clark, Dallinga-Thie, Daniel Felmlee, Dao Thi, Dienes, Enjoji, Esau, Forde, Fraser, Goldwasser, Grove, Haid, Harrison, Herker, Hijikata, Hirata, Hsu, Huang, Icard, Ishibashi, Jopling, Kaito, Kanto, Koutsoudakis, Lambert, Lanford, Lin, Lindenbach, Mancone, Martin, Marzouk, Mathieu Lefevre, McHutchison, Meex, Meunier, Miyanari, Mohamed Hafirassou, Nahmias, Nakamuta, Nishimura, Packard, Pecheur, Petit, Poynard, Prentoe, Pumeechockchai, Ramcharran, Reiss, Rocha-Perugini, Roe, Romero-Brey, Sakamoto, Sarasin-Filipowicz, Scholtes, Schuster, Serfaty, Sezaki, Shavinskaya, Shi, Shimakami, Stanford, Targett-Adams, Thomas Baumert, Thomssen, Tsai, Voisset, Wakita, Weng, Westin, Ye, Zeisel   +88 more
core   +7 more sources

Raised serum transaminases during treatment with pegylated interferon for chronic hepatiti C [PDF]

, 2016
Introduction : Serum transaminases rose significantly in 7 patients with chronic hepatitis C, genotypes 2 and 3, who were treated with pegylated interferon and ribavirin. Methods : 219 patients with chronic hepatitis C, genotypes 2 and 3, were treated
Datta, S., Mandalou, P., Mills, P.R., Spence, E.   +3 more
core   +1 more source

Transcription Factor MafB Suppresses Type I Interferon Production by CD14+ Monocytes in Patients With Chronic Hepatitis C

Frontiers in Microbiology, 2019
Transcription factor MafB regulates differentiation and activity of monocytes/macrophage and is associated with the development of atherosclerosis and cancers.
Tie-Mei Liu, Han Wang, Dong-Na Zhang, Guang-Ze Zhu   +3 more
doaj   +1 more source

Vitamin D as One of Predicators of the Stable Viral Response to Antiviral Therapy in Patients with Chronis Hepatitis С [PDF]

, 2016
Chronic hepatitis C (CHC) it is not exceptionally medical problem but a significant social and economic threat, taking into account the unfavorable consequences of this disease: cirrhosis and hepatocellular carcinoma.
Androsova, O. (Olga), Davydyuk, I. (Irina), Moroz, L. (Larisa), Musaev, E. E. (Eltun)   +3 more
core  

Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C. [PDF]

, 2012
The current standard of care (SoC) for chronic hepatitis C, i.e. the combination of a pegylated-interferon (PEG-IFN) with ribavirin (RBV), may activate underlying autoimmune conditions.
ALESSI, Nicola, CABIBI, Daniela, MACALUSO, Fabio Salvatore   +2 more
core   +1 more source

Clinical epidemiology of extrahepatic manifestations of chronic hepatitis C virus infection

Медицинский совет, 2020
Extrahepatic manifestations occur in more than half of patients with chronic hepatitis C virus infection and may be no less dangerous to the health and life of the patient than the isolated pathology of the liver.
V. V. Tsvetkov, I. I. Tokin, S. A. Pozdnjakova   +2 more
doaj   +1 more source

Health-Related Quality of Life in Portuguese Patients with Chronic Hepatitis C [PDF]

, 2016
INTRODUCTION: Chronic hepatitis C virus (HCV) infection impacts multiple health and psychosocial dimensions and encompasses a significant overall burden as it progresses to advanced stages of hepatic disease.
Pedroto, I., Rei, A., Rocha, M.
core   +1 more source

Thrombocytopenia in end-stage renal disease and chronic viral hepatitis B or C [PDF]

, 2018
Objectives. We evaluated platelet counts in end-stage renal disease and chronic viral hepatitis. Materials and Methods. We studied 70 patients with end-stage renal disease and chronic viral hepatitis and compared them to a control group of 45 patients ...
Breaban, Iulia, Ciulei, George, Cozma, Angela, Negrean, Vasile, Orasan, Olga Hilda, Orasan, Remus Aurel, Patiu, Ioan Mihai, Sampelean, Dorel, Secara, Sorina Cezara, Sitar Taut, Adela, Stefan, Andreea Maria, Tarmure Sarlea, Simina, Urian, Laura   +12 more
core   +1 more source

Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study [PDF]

, 2018
Background/Aims: The hepatitis C virus (HCV) infection is important cause of chronic hepatitis. Liver biopsy is considered the gold standard for assessment of fibrosis but this procedure is an invasive procedure.
Akhan, S., Aydoǧdu, Ö., Baykam, N., Beslen, N., Bostanci, F., Candan, M., Daǧli, Ö., Demirdal, T., Duyar, E., Erdoǧan, S., Gökal, A.A., Güner, R., Gürbüz, Y., Inan, D., Kaya, A., Kaya, S., Kiliç, S., Kinikli, S., Kuruüzüm, Z., Kökoǧlu, Ö.F., Köksal, I., Leblebicioǧlu, H., Namiduru, M., Parlak, M., Sehmen, E., Tabak, F., Tarakçi, H., Turgut, Hüseyin, Ural, O., Yamazhan, T., Yilmaz, G., Yuluǧkural, Z., Önlen, Y., Özdemir, D., Özdener, F.   +34 more
core   +1 more source